Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: We investigated the incidences of pericardial and pleural effusions after definitive radiotherapy with or without concurrent chemotherapy were analyzed retrospectively. Methods: One hundred and forty-seven patients with esophageal cancer received definitive radiotherapy or concurrent chemoradiotherapy (CCR). Follow-up chest Computed Tomography scans were reviewed to detect pericardial and pleural effusions. Adverse events were graded according to the Radiation Therapy Oncology Group Common Toxicity Criteria. Results: The median follow-up was 34 (range, 6 to 84) months. Numbers of eligible patients evaluated for pericardial and pleural effusions were 107 and 101, respectively. Pericardial effusions exceeding grade 1 and grade 2 toxicities were observed in 46 (43%) and 15 (14%) patients, respectively. The corresponding numbers for pleura! effusions were 44 (44%) and 18 (18%). Onset of effusion ranged from 1 to 65 months after treatment. Multivariate analysis identified radiation field width of the mediastinum exceeding 8 cm as a significant risk factor for both pericardial and pleural effusions. Age and field length exceeding 20 cm were identified as independent risk factors for pleural effusion. Conclusions: Pericardial and pleural effusions after radiotherapy or CCR are occasionally recognized as adverse events in patients with esophageal cancer. The mediastinal radiation field width can be a simple indicator for predicting those adverse events.

Original languageEnglish
Pages (from-to)447-453
Number of pages7
JournalJournal of Radiation Research
Volume53
Issue number3
DOIs
Publication statusPublished - 2012 May

Fingerprint

Pericardial Effusion
Pleural Effusion
Esophageal Neoplasms
radiation therapy
Radiotherapy
cancer
toxicity
radiation distribution
grade
pleurae
mediastinum
Chemoradiotherapy
chest
chemotherapy
Radiation
Radiation Oncology
Pleura
incidence
tomography
Mediastinum

Keywords

  • Chemoradiotherapy
  • Esophageal cancer
  • Pericardiai effusion
  • Pleural effusion
  • Radiotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Health, Toxicology and Mutagenesis

Cite this

@article{6452775d73a0479e8ffa3598db1ddf84,
title = "Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer",
abstract = "Purpose: We investigated the incidences of pericardial and pleural effusions after definitive radiotherapy with or without concurrent chemotherapy were analyzed retrospectively. Methods: One hundred and forty-seven patients with esophageal cancer received definitive radiotherapy or concurrent chemoradiotherapy (CCR). Follow-up chest Computed Tomography scans were reviewed to detect pericardial and pleural effusions. Adverse events were graded according to the Radiation Therapy Oncology Group Common Toxicity Criteria. Results: The median follow-up was 34 (range, 6 to 84) months. Numbers of eligible patients evaluated for pericardial and pleural effusions were 107 and 101, respectively. Pericardial effusions exceeding grade 1 and grade 2 toxicities were observed in 46 (43{\%}) and 15 (14{\%}) patients, respectively. The corresponding numbers for pleura! effusions were 44 (44{\%}) and 18 (18{\%}). Onset of effusion ranged from 1 to 65 months after treatment. Multivariate analysis identified radiation field width of the mediastinum exceeding 8 cm as a significant risk factor for both pericardial and pleural effusions. Age and field length exceeding 20 cm were identified as independent risk factors for pleural effusion. Conclusions: Pericardial and pleural effusions after radiotherapy or CCR are occasionally recognized as adverse events in patients with esophageal cancer. The mediastinal radiation field width can be a simple indicator for predicting those adverse events.",
keywords = "Chemoradiotherapy, Esophageal cancer, Pericardiai effusion, Pleural effusion, Radiotherapy",
author = "Junichi Fukada and Naoyuki Shigematsu and Toshio Ohashi and Yutaka Shiraishi and Hiroya Takeuchi and Osamu Kawaguchi and Yuukou Kitagawa",
year = "2012",
month = "5",
doi = "10.1269/jrr.11194",
language = "English",
volume = "53",
pages = "447--453",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "3",

}

TY - JOUR

T1 - Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer

AU - Fukada, Junichi

AU - Shigematsu, Naoyuki

AU - Ohashi, Toshio

AU - Shiraishi, Yutaka

AU - Takeuchi, Hiroya

AU - Kawaguchi, Osamu

AU - Kitagawa, Yuukou

PY - 2012/5

Y1 - 2012/5

N2 - Purpose: We investigated the incidences of pericardial and pleural effusions after definitive radiotherapy with or without concurrent chemotherapy were analyzed retrospectively. Methods: One hundred and forty-seven patients with esophageal cancer received definitive radiotherapy or concurrent chemoradiotherapy (CCR). Follow-up chest Computed Tomography scans were reviewed to detect pericardial and pleural effusions. Adverse events were graded according to the Radiation Therapy Oncology Group Common Toxicity Criteria. Results: The median follow-up was 34 (range, 6 to 84) months. Numbers of eligible patients evaluated for pericardial and pleural effusions were 107 and 101, respectively. Pericardial effusions exceeding grade 1 and grade 2 toxicities were observed in 46 (43%) and 15 (14%) patients, respectively. The corresponding numbers for pleura! effusions were 44 (44%) and 18 (18%). Onset of effusion ranged from 1 to 65 months after treatment. Multivariate analysis identified radiation field width of the mediastinum exceeding 8 cm as a significant risk factor for both pericardial and pleural effusions. Age and field length exceeding 20 cm were identified as independent risk factors for pleural effusion. Conclusions: Pericardial and pleural effusions after radiotherapy or CCR are occasionally recognized as adverse events in patients with esophageal cancer. The mediastinal radiation field width can be a simple indicator for predicting those adverse events.

AB - Purpose: We investigated the incidences of pericardial and pleural effusions after definitive radiotherapy with or without concurrent chemotherapy were analyzed retrospectively. Methods: One hundred and forty-seven patients with esophageal cancer received definitive radiotherapy or concurrent chemoradiotherapy (CCR). Follow-up chest Computed Tomography scans were reviewed to detect pericardial and pleural effusions. Adverse events were graded according to the Radiation Therapy Oncology Group Common Toxicity Criteria. Results: The median follow-up was 34 (range, 6 to 84) months. Numbers of eligible patients evaluated for pericardial and pleural effusions were 107 and 101, respectively. Pericardial effusions exceeding grade 1 and grade 2 toxicities were observed in 46 (43%) and 15 (14%) patients, respectively. The corresponding numbers for pleura! effusions were 44 (44%) and 18 (18%). Onset of effusion ranged from 1 to 65 months after treatment. Multivariate analysis identified radiation field width of the mediastinum exceeding 8 cm as a significant risk factor for both pericardial and pleural effusions. Age and field length exceeding 20 cm were identified as independent risk factors for pleural effusion. Conclusions: Pericardial and pleural effusions after radiotherapy or CCR are occasionally recognized as adverse events in patients with esophageal cancer. The mediastinal radiation field width can be a simple indicator for predicting those adverse events.

KW - Chemoradiotherapy

KW - Esophageal cancer

KW - Pericardiai effusion

KW - Pleural effusion

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84863468174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863468174&partnerID=8YFLogxK

U2 - 10.1269/jrr.11194

DO - 10.1269/jrr.11194

M3 - Article

VL - 53

SP - 447

EP - 453

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 3

ER -